FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385236399> ?p ?o ?g. }

• W4385236399 abstract "<p>Validation of IRS to stratify anti-PD-(L)1 monotherapy benefit in patients with advanced solid tumors. <b>A,</b> Clinical characteristics of the anti-PD-(L)1 monotherapy validation cohort are shown in an alluvial diagram. All patients with available clinical molecular profiling data necessary for IRS (TMB and normalized expression of <i>PD-1</i>, <i>PD-L1</i>, <i>ADAM12,</i> and <i>TOP2A</i> from in-parallel qTP) from FFPE tumor tissue enrolled in the Strata Trial (NCT03061305) and treated with systemic anti-PD-(L)1 monotherapy were considered. Patients in previous IRS discovery or validation were excluded. The locked IRS model and thresholds were used to assign IRS-L (light blue) or IRS-H (increased benefit; dark blue) status. For the 352 eligible patients, IRS status, MSI/TMB status (MSI-H or TMB-H as MSI/TMB-H), type of anti-PD-(L)1 therapy [pembrolizumab (pembro) vs. other anti-PD-(L)1], systemic line of anti-PD-(L)1 therapy, and tumor type [all tumor types with >15 samples considered individually: NSCLC, cancer of unknown primary (CUP), bladder cancer (Blad.), melanoma (Mel.), head and neck cancer (H&N), and EGC; remaining 25 other tumor types considered together] are shown. Stratum are colored by IRS status. IRS stratifies anti-PD-(L)1 monotherapy clinical benefit by rwPFS (by time to next therapy; B) and OS (C). <b>B,</b> Anti-PD-(L)1 monotherapy rwPFS stratified by IRS group is shown by unadjusted Kaplan–Meier analysis, with the aHR [adjusted for age, sex assigned at birth, line of therapy, tumor type and anti-PD-(L)1 therapy type], 95% CI and <i>P</i> value for IRS status (IRS-H vs. IRS-L) shown. The number (<i>n</i>) of patients, events, and median rwPFS (with 95% CI) for each group are shown. Forest plot analyses of rwPFS by IRS status in key subgroups are shown below (Remaining 4 = Blad., Mel., H&N, and EGC). Significant associations are shown by filled in aHR estimates. <b>C,</b> As in B, except assessing OS.</p>" @default.
• W4385236399 created "2023-07-26" @default.
• W4385236399 creator A5002282387 @default.
• W4385236399 creator A5006591586 @default.
• W4385236399 creator A5006626512 @default.
• W4385236399 creator A5007133435 @default.
• W4385236399 creator A5010766249 @default.
• W4385236399 creator A5011310452 @default.
• W4385236399 creator A5011957277 @default.
• W4385236399 creator A5016540674 @default.
• W4385236399 creator A5016973435 @default.
• W4385236399 creator A5019976583 @default.
• W4385236399 creator A5021347143 @default.
• W4385236399 creator A5022987543 @default.
• W4385236399 creator A5023767403 @default.
• W4385236399 creator A5024459006 @default.
• W4385236399 creator A5034441163 @default.
• W4385236399 creator A5035724058 @default.
• W4385236399 creator A5036173597 @default.
• W4385236399 creator A5040117135 @default.
• W4385236399 creator A5042877747 @default.
• W4385236399 creator A5043991433 @default.
• W4385236399 creator A5050180604 @default.
• W4385236399 creator A5051200199 @default.
• W4385236399 creator A5051542399 @default.
• W4385236399 creator A5055078293 @default.
• W4385236399 creator A5057978911 @default.
• W4385236399 creator A5062386303 @default.
• W4385236399 creator A5066238218 @default.
• W4385236399 creator A5066501377 @default.
• W4385236399 creator A5066873406 @default.
• W4385236399 creator A5068238406 @default.
• W4385236399 creator A5069304786 @default.
• W4385236399 creator A5071796883 @default.
• W4385236399 creator A5078890913 @default.
• W4385236399 creator A5086422029 @default.
• W4385236399 creator A5087236483 @default.
• W4385236399 creator A5091829641 @default.
• W4385236399 creator A5092385371 @default.
• W4385236399 creator A5092387595 @default.
• W4385236399 date "2023-07-25" @default.
• W4385236399 modified "2023-09-23" @default.
• W4385236399 title "FIGURE 1 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit" @default.
• W4385236399 doi "https://doi.org/10.1158/2767-9764.23745832.v1" @default.
• W4385236399 hasPublicationYear "2023" @default.
• W4385236399 type Work @default.
• W4385236399 citedByCount "0" @default.
• W4385236399 crossrefType "posted-content" @default.
• W4385236399 hasAuthorship W4385236399A5002282387 @default.
• W4385236399 hasAuthorship W4385236399A5006591586 @default.
• W4385236399 hasAuthorship W4385236399A5006626512 @default.
• W4385236399 hasAuthorship W4385236399A5007133435 @default.
• W4385236399 hasAuthorship W4385236399A5010766249 @default.
• W4385236399 hasAuthorship W4385236399A5011310452 @default.
• W4385236399 hasAuthorship W4385236399A5011957277 @default.
• W4385236399 hasAuthorship W4385236399A5016540674 @default.
• W4385236399 hasAuthorship W4385236399A5016973435 @default.
• W4385236399 hasAuthorship W4385236399A5019976583 @default.
• W4385236399 hasAuthorship W4385236399A5021347143 @default.
• W4385236399 hasAuthorship W4385236399A5022987543 @default.
• W4385236399 hasAuthorship W4385236399A5023767403 @default.
• W4385236399 hasAuthorship W4385236399A5024459006 @default.
• W4385236399 hasAuthorship W4385236399A5034441163 @default.
• W4385236399 hasAuthorship W4385236399A5035724058 @default.
• W4385236399 hasAuthorship W4385236399A5036173597 @default.
• W4385236399 hasAuthorship W4385236399A5040117135 @default.
• W4385236399 hasAuthorship W4385236399A5042877747 @default.
• W4385236399 hasAuthorship W4385236399A5043991433 @default.
• W4385236399 hasAuthorship W4385236399A5050180604 @default.
• W4385236399 hasAuthorship W4385236399A5051200199 @default.
• W4385236399 hasAuthorship W4385236399A5051542399 @default.
• W4385236399 hasAuthorship W4385236399A5055078293 @default.
• W4385236399 hasAuthorship W4385236399A5057978911 @default.
• W4385236399 hasAuthorship W4385236399A5062386303 @default.
• W4385236399 hasAuthorship W4385236399A5066238218 @default.
• W4385236399 hasAuthorship W4385236399A5066501377 @default.
• W4385236399 hasAuthorship W4385236399A5066873406 @default.
• W4385236399 hasAuthorship W4385236399A5068238406 @default.
• W4385236399 hasAuthorship W4385236399A5069304786 @default.
• W4385236399 hasAuthorship W4385236399A5071796883 @default.
• W4385236399 hasAuthorship W4385236399A5078890913 @default.
• W4385236399 hasAuthorship W4385236399A5086422029 @default.
• W4385236399 hasAuthorship W4385236399A5087236483 @default.
• W4385236399 hasAuthorship W4385236399A5091829641 @default.
• W4385236399 hasAuthorship W4385236399A5092385371 @default.
• W4385236399 hasAuthorship W4385236399A5092387595 @default.
• W4385236399 hasBestOaLocation W43852363991 @default.
• W4385236399 hasConcept C121608353 @default.
• W4385236399 hasConcept C126322002 @default.
• W4385236399 hasConcept C143998085 @default.
• W4385236399 hasConcept C2777658100 @default.
• W4385236399 hasConcept C2777701055 @default.
• W4385236399 hasConcept C2780057760 @default.
• W4385236399 hasConcept C502942594 @default.
• W4385236399 hasConcept C71924100 @default.
• W4385236399 hasConceptScore W4385236399C121608353 @default.
• W4385236399 hasConceptScore W4385236399C126322002 @default.
• W4385236399 hasConceptScore W4385236399C143998085 @default.
• W4385236399 hasConceptScore W4385236399C2777658100 @default.
• W4385236399 hasConceptScore W4385236399C2777701055 @default.

• next